$IMDX

Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics, which operates as iMDx, develops molecular diagnostic tests and provides laboratory testing and assay development services. Its targeted customers include hospitals, transplant centers, laboratories, researchers, and life sciences and biotechnology companies. Its main near-term focus is organ transplant rejection testing, with products under the GraftAssure brand: GraftAssureCore, a laboratory-developed test performed at its Franklin, Tennessee laboratory; GraftAssureIQ, a research-use-only kit; and GraftAssureDx, an in vitro diagnostic kit in development. The tests measure donor-derived cell-free DNA, a biomarker associated with transplanted organ rejection. The company also has oncology assays, DetermaIO and DetermaCNI, and conducts other testing and assay development through its Laboratory Services operations. Insight Molecular Diagnostics earns money from laboratory testing and services and sales of test kits. Its Franklin laboratory performs GraftAssureCore testing, while its kitted products are designed for use by local laboratories. The company’s principal executive and administrative offices are in Nashville, Tennessee. It also has research and development laboratories in Nashville and Göttingen, Germany.

6
1
6
$6.0M
—
BROADWOOD PARTNERS, L.P.
0%
See all $IMDX insider activity →
Med

Healthcare Stocks In Focus - ITOC +17%, EVAX +13%, IMDX +10%; AKAN And EVH See Trading Activity

Several healthcare and biotech stocks saw significant moves. Akanda Corp. (AKAN) rose 27.99% on high volume, iTonic Holdings (ITOC) gained 13.33% post-reverse split, Evaxion A/S (EVAX) advanced 14.29% on strategic shift, Insight Molecular Diagnostics (IMDX) climbed 8.90% on study enrollment, and Evolent Health (EVH) rebounded 14.14% after an analyst upgrade.

IMDx Enrolls First Patients In 5,000-Participant GALACTIC Kidney Transplant Study

Insight Molecular Diagnostics (IMDX) began its 5,000-patient GALACTIC study for GraftAssure, a kidney transplant rejection test. UCLA Medical Center enrolled the first patients. The study aims to validate GraftAssure's performance in real-world settings and support FDA review of GraftAssureDx. IMDX's stock is up 6.22% to $1.76.

IMDX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 13 news stories mentioning IMDX (Insight Molecular Diagnostics Inc.). Coverage has been balanced: 6 bullish, 1 neutral, and 6 bearish.

Recent IMDX coverage spans market movers, insider activity and corporate actions.

In the last 30 days, IMDX insiders filed 2 SEC Form 4 transactions — 2 purchases ($6.0M) and no sales. The most active reporter was BROADWOOD PARTNERS, L.P. with 2 filings.

What's driving IMDX

  • Enrollment start is a tangible clinical-development milestone that can improve probability-weighted outlook for the diagnostic franchise.

    rttnews.com · Nov 20, 2026

  • The enrollment initiates clinical validation that could drive future adoption and revenue.

    rttnews.com · Nov 20, 2026

  • The filing is a primary insider-ownership signal, but the disclosed share count is 0 and price is not provided, limiting immediate trading impact.

    SEC EDGAR · Nov 19, 2026

  • The filing signals continued insider/large-holder accumulation, which can be read as confidence, but it is not a fundamental operating update.

    SEC EDGAR · Nov 19, 2026

  • Capital raise and revenue growth support a short‑term rally.

    rttnews.com · Nov 19, 2026

AlphAI scores every news story that mentions IMDX with an AI model for sentiment and relevance, and aggregates insider trades from Insight Molecular Diagnostics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IMDX

Score
$IMDXMedOffering· proposed

Insight Molecular Diagnostics Inc. (IMDX): Entry into a Material Definitive Agreement

Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Insight Molecular Diagnostics Announces Proposed Public Offering NASHVILLE, Tenn. – November 16, 2026 – Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an underwritten public offeri

Insight Molecular (IMDX) Q3 2026 Earnings Call Transcript

Insight Molecular (IMDX) reported Q3 2026 earnings, highlighting progress in the GALACTIC study, FDA review, and financial performance. The company expects to submit additional information to the FDA by January 21, 2027. Operating expenses peaked in Q4 2025, with R&D costs decreasing to $3.8 million in Q3 2026. The company aims to expand its GraftAssure platform and believes it has strong clinical demand, reimbursement, and IP protection.

What Oncocyte (IMDX) Said on Its Q3 Earnings Call

Oncocyte (IMDX) reported on its Q3 earnings call that the FDA requested additional biopsy slide reviews, pausing its review clock. The company expects to restart the process soon and aims to launch its product shortly after authorization. UCLA and other sites are enrolling patients in the GALACTIC registry, targeting an 80% positive predictive value. The company also discussed its reimbursement strategy and plans for heart and European markets.

Related tickers